Halting Neurodegeneration with
Disease Altering Therapeutics
Welcome to AcureX Therapeutics
AcureX Therapeutics is a pharmaceutical company with a mission to halt major neurodegenerative diseases driven by impaired mitophagy, starting with Parkinson’s disease (PD). A large body of evidence now supports that impairment of mitophagy, the normal process by which cells dispose of dysfunctional mitochondria, plays a significant role in the pathogenesis of PD and other diseases.
AcureX’s platform and founding intellectual property are based on a Stanford University breakthrough discovery enabling the identification of druggable targets responsible for defects in mitophagy. AcureX’s platform has generated two oral small-molecule therapeutic programs that cross the BBB, reactivate mitophagy, and protect PD patient-derived neurons. AcureX’s lead program has begun IND-enabling studies, and the second program to a distinct target is shortly behind. In addition to PD, AcureX has demonstrated value for this approach in other diseases where mitophagy is implicated, opening future market opportunities beyond PD and neurodegeneration.
AcureX’s clinical development plan leverages its proprietary biomarker of mitophagy that can be measured in the periphery and is significantly altered in PD patients, including patients with LRRK2 and GBA PD. AcureX’s mitophagy biomarker changes with drug treatment, enabling early efficacy insights and de-risking in phase 1b rather than in phase 2b trials. AcureX's biomarker for pre-selection and stratification of patients combined with our drug treatment will be a significant step forward in bringing personalized medicine to treating CNS diseases.
Supported by $5.5M from the Michael J. Fox Foundation for Parkinson’s Research, the Silverstein Foundation for Parkinson's with GBA, NIH grant funding and private funding.